Special Issue "Pulmonary Arterial Hypertension (PAH)"
A special issue of Diseases (ISSN 2079-9721).
Deadline for manuscript submissions: closed (15 February 2014)
Dr. Allan Lawrie
Department of Cardiovascular Science, University of Sheffield, UK
Interests: pathobiology of PAH; biomarkers; disease models; inflammatory mechanisms; apoptosis; autophagy
Pulmonary arterial hypertension (PAH) is a rare but devastating disease that carries a terrible prognosis. Pathologically PAH is characterized by sustained vasoconstriction and progressive obliteration of small resistance pulmonary arteries. Current treatments target the sustained vasoconstriction but the prognosis remains poor. There is currently limited information on biomarkers that indicate a patient response to these therapies. There is also an unmet need to develop new treatments that specifically target the progressive vasculopathy in these patients.
This Special Issue will provide an Open Access opportunity to publish research work and review articles related to the novel biomarkers, new molecular insights and potential therapeutic targets.
Dr. Allan Lawrie
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.
- pulmonary arterial hypertension (PAH)
- disease models
- inflammatory mechanisms
Diseases 2014, 2(2), 120-147; doi:10.3390/diseases2020120
Received: 12 April 2014; in revised form: 28 April 2014 / Accepted: 30 April 2014 / Published: 28 May 2014| PDF Full-text (555 KB) | HTML Full-text | XML Full-text
Article: NF-κB Activation Exacerbates, but Is not Required for Murine Bmpr2-Related Pulmonary Hypertension
Diseases 2014, 2(2), 148-167; doi:10.3390/diseases2020148
Received: 18 April 2014; in revised form: 20 May 2014 / Accepted: 21 May 2014 / Published: 30 May 2014| PDF Full-text (1747 KB) | HTML Full-text | XML Full-text
Diseases 2014, 2(3), 243-259; doi:10.3390/diseases2030243
Received: 12 June 2014; in revised form: 21 July 2014 / Accepted: 25 July 2014 / Published: 31 July 2014| PDF Full-text (264 KB) | HTML Full-text | XML Full-text
Article: TRAIL Deficient Mice Are Protected from Sugen/Hypoxia Induced Pulmonary Arterial Hypertension
Diseases 2014, 2(3), 260-273; doi:10.3390/diseases2030260
Received: 11 March 2014; in revised form: 15 July 2014 / Accepted: 28 July 2014 / Published: 31 July 2014| PDF Full-text (2592 KB) | HTML Full-text | XML Full-text
Last update: 7 August 2013